MintNeuro and Motif Neurotech announce partnership and multi-year supply deal for miniature psychiatric BCI chips
Summary
London-based MintNeuro and Houston-based Motif Neurotech announced a formal partnership and multi-year commercial supply agreement on April 30, 2026 to accelerate the clinical availability of therapeutic BCIs for mental health. MintNeuro's ultra-low-power, compact neural interface chips — already validated in Motif's pre-clinical work — will be integrated into Motif's XCS wirelessly-powered brain implant for treatment-resistant depression. The partnership follows Motif receiving FDA Breakthrough Device Designation for XCS and FDA IDE approval for the RESONATE clinical trial. The collaboration includes aligning successive MintNeuro chip generations with Motif's clinical development roadmap.
Why it matters
This partnership creates the chip supply chain for what could become the world's first miniaturised psychiatric brain implant. MintNeuro provides the key enabling semiconductor technology that makes Motif's blueberry-sized implant physically achievable — their ultra-low-power ICs are the reason the device can be wirelessly powered without a large chest battery. The multi-year supply agreement also signals commercial-stage supply chain planning, not just research collaboration.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial